We
aimed to investigate whether polydatin could suppress stress-induced
depression- and anxiety-like behaviors in a mouse model. Mice were
divided into the control group, chronic unpredictable mild stress
(CUMS) exposure group, and CUMS mice treated with polydatin group.
Following CUMS exposure and polydatin treatment, mice were subjected
to behavioral assays to assess depressive-like and anxiety-like behaviors.
Synaptic function was determined by the levels of brain-derived neurotrophic
factor (BDNF), postsynaptic density protein 95 (PSD95), and synaptophysin
(SYN) in the hippocampus and cultured hippocampal neurons. The number
and length of dendrites were assessed in cultured hippocampal neurons.
Finally, we investigated the effect of polydatin on CUMS-induced inflammation
and oxidative stress in the hippocampus by measuring inflammatory
cytokine levels, oxidative stress markers such as reactive oxygen
species, glutathione peroxidase, catalase, and superoxide dismutase,
as well as components of the Nrf2 signaling pathway. Polydatin alleviated
CUMS-induced depressive-like behaviors in forced swimming, tail suspension
and sucrose preference tests, and anxiety-like behaviors in marble-burying
and elevated plus maze tests. Polydatin increased the number and length
of dendrites of cultured hippocampal neurons from mice exposed to
CUMS and alleviated CUMS-induced synaptic deficits by restoring BDNF,
PSD95, and SYN levels in vivo and in vitro. Importantly, polydatin
inhibited CUMS-induced hippocampal inflammation and oxidative stress
and suppressed the activation of NFκB and Nrf2 pathways. Our
study suggests that polydatin may be an effective drug for the treatment
of affective disorders through inhibiting neuroinflammation and oxidative
stress. Our current findings warrant further study to investigate
the potential clinical application of polydatin.